Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Issues 2023 Shareholder Letter

ACCESS Newswire January 11, 2023

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

ACCESS Newswire January 4, 2023

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

ACCESS Newswire December 19, 2022

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

ACCESS Newswire December 7, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

ACCESS Newswire December 5, 2022

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

ACCESS Newswire November 14, 2022

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

ACCESS Newswire November 14, 2022

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

ACCESS Newswire October 31, 2022

Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study

ACCESS Newswire October 28, 2022

Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference

Newsfile October 12, 2022

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

ACCESS Newswire September 22, 2022

Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022

ACCESS Newswire September 21, 2022

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

ACCESS Newswire September 8, 2022

Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting

ACCESS Newswire September 6, 2022

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

PR Newswire August 31, 2022

Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline

ACCESS Newswire August 31, 2022

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

ACCESS Newswire August 24, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

ACCESS Newswire August 23, 2022

Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call

ACCESS Newswire August 17, 2022

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

ACCESS Newswire August 11, 2022